Hospira appeals against $70m Amgen verdict
02-10-2017
Amgen secures $70m in biosimilar clash with Hospira
26-09-2017
Avosb / iStockphoto.com
The US Court of Appeals for the Federal Circuit has rejected a request by Amgen to compel discovery from Hospira over a biosimilar.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Amgen, Hospira, patent, US Court of Appeals for the Federal Circuit, biosimilar, Biologics Price Competition and Innovation Act, anaemia
